Monotherapy for partial epilepsy: focus on levetiracetam

References

• AlsaadiTMShatzelAMarquezAVClinical experience of levetiracetam monotherapy for adults with epilepsy: 1-year follow-up studySeizure2005141394215694569
   PubMed Web of Science ®Google Scholar
• BaulacMBrodieMJChristianEELevetiracetam intravenous infusion as as alternative to oral dosing in patients with partial-onset seizuresEpilepsia2007485899217326794
   PubMed Web of Science ®Google Scholar
• Ben-MenachemEFalterUEfficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapyEpilepsia20004112768311051122
   PubMed Web of Science ®Google Scholar
• BrodieMJPeruccaERyvilinPComparison of levetiracetam and controlled release carbamazepine in newly diagnosed epilepsyNeurology200768402817283312
   PubMed Web of Science ®Google Scholar
• BrowneTRSzaboGKLeppikIEAbsence of pharmacokinetic drug interaction of levetiracetam with phenytoin in patients with epilepsy determined by new techniqueJ Clin Pharmacol200040590510868309
   PubMed Web of Science ®Google Scholar
• CereghinoJJBitonVAbou-KhalilBLevetiracetam for partial seizures: results of a double-blind, randomized clinical trialNeurology2000552364210908898
   PubMed Web of Science ®Google Scholar
• DooleyMPloskerGLLevetiracetam: a review of its adjunctive use in the management of partial onset seizuresDrugs2000608719311085199
   PubMed Web of Science ®Google Scholar
• FrenchJArrigoCRapid onset of action of levetiracetam in refractory epilepsy patientsEpilepsia200546324615679515
   PubMed Web of Science ®Google Scholar
• FrenchJEdrichPCramerJAA systematic review of the safety profile of levetiracetam: a new antiepileptic drugEpilepsy Res200147779011673023
   PubMed Web of Science ®Google Scholar
• FrenchJAKannerAMBautistaJEfficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsyNeurology2004a6212526015111659
   PubMed Web of Science ®Google Scholar
• FrenchJAKannerAMBautistaJEfficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsyNeurology2004b6212617315111660
   PubMed Web of Science ®Google Scholar
• GidalBEBaltèsEOtoulCEffect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trialsEpilepsy Res20056411115823510
   PubMed Web of Science ®Google Scholar
• GlauserTAAyalaREltermanRDDouble-blind, randomized, placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizuresNeurology20066616546016641323
   PubMed Web of Science ®Google Scholar
• GlauserTAPellockJMBebinEMEfficacy and safety of levetiracetam in children with partial seizures: an open-label trialEpilepsia2002435182412027913
   PubMed Web of Science ®Google Scholar
• GowerAJHirschEBoehrerAEffects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsyEpilepsy Res199522207138991787
   PubMed Web of Science ®Google Scholar
• GowerAJNoyerMVerloesRUCB L059, a novel anti-convulsant drug: pharmacological profile in animalsEur J Pharmacol19922221932031451732
   PubMed Web of Science ®Google Scholar
• HardenCSafety profile of levetiracetamEpilepsia200142Suppl 436911564124
   PubMed Web of Science ®Google Scholar
• HovingaCALevetiracetam: a novel antiepileptic drugPharmacotherapy20012113758811714211
   PubMed Web of Science ®Google Scholar
• Kasteleijn-Nolst TrenitéDGAMarescauxCStodieckSPhotosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetamEpilepsy Res199625225308956920
   PubMed Web of Science ®Google Scholar
• Keppra™ (250 mg, 500 mg, 1000 mg)Summary of product characteristics2000bBrussels, BelgiumUCB SA June 2000
   Google Scholar
• Keppra™ levetiracetam 250, 500, 750 mg tabletsPrescribing information2000aBrussels, BelgiumUCB Pharma
   Google Scholar
• KlitgaardHMatagneAGobertJEvidence for a unique profile of levetiracetam in rodent models of seizures and epilepsyEur J Pharmacol19983531912069726649
   PubMed Web of Science ®Google Scholar
• KlitgaardHLevetiracetam: the preclinical profile of a new class of antiepileptic drugs?Epilepsia200142Suppl 4131811564119
   PubMed Web of Science ®Google Scholar
• KossoffEHBergeyGKFreemanJMLevetiracetam psychosis in children with epilepsyEpilepsia2001421611311879376
   PubMed Web of Science ®Google Scholar
• KrakowDWalkerWOtoulCLong-term continuation of levetiracetam in patients with refractory epilepsyNeurology2001561772411425954
   PubMed Web of Science ®Google Scholar
• LabateAColosimoEGambardellaALevetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label studySeizure200615214816420982
   PubMed Web of Science ®Google Scholar
• LeppikIEBitonVSanderJWLevetiracetam and partial seizure subtypes: pooled data from three randomized, placebo-controlled trialsEpilepsia2003441585714636332
   PubMed Web of Science ®Google Scholar
• LevyRHRagueneau-MajlessiIBaltesERepeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteersEpilepsy Res20014693911463510
   PubMed Web of Science ®Google Scholar
• LöscherWHönackDRundfeldtCAntiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsyJ Pharmacol Exp Ther199828447499454787
   PubMed Web of Science ®Google Scholar
• LöscherWHönackDProfile of ucb L059, a novel anticonvulsant drug, in models of partial and generalised epilepsy in mice and ratsEur J Pharmacol1993232147588467854
   PubMed Web of Science ®Google Scholar
• LuszczkiJJAndres-MachMMRatnarajNLevetiracetam and felbamate interact both pharmacodynamically and pharmacokinetically: an isobolographic analysis in the mouse maximal electroshock modelEpilepsia2007488061517284299
   PubMed Web of Science ®Google Scholar
• MadejaMMargineanouDKlitgaardHEffect of levetiracetam on voltage-gated, potassium channels: a novel anti-epileptic mechanism?Epilepsia200142suppl 219
   Google Scholar
• MulaMTrimbleMRYuenAPsychiatric adverse events during levetiracetam therapyNeurology200361704612963770
   PubMed Web of Science ®Google Scholar
• NeyensLGJAlphertsWCJAldenkampAPCognitive effects of a new pyrrolidine derivative (levetiracetam) in patients with epilepsyProg Neuro-Psychopharmacol Biol Psychiatry1995194119
   PubMed Web of Science ®Google Scholar
• NicolasJMCollartPGerinBIn vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agentDrug Metab Dispos19992725049929511
   PubMed Web of Science ®Google Scholar
• NiespodzianyIKlitgaardHMargineanuD-GLevetiracetam inhibits the higher-voltage-activated Ca++ current in pyramidal neurons of rat hippocampal slicesNeurosci Lett20013065811403944
   PubMed Web of Science ®Google Scholar
• NoyerMGillardMMatagneAThe novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranesEur J Pharmacol1995286137468605950
   PubMed Web of Science ®Google Scholar
• PellockJMGlauserTABebinEMPharmacokinetic study of levetiracetam in childrenEpilepsia2001421574911879369
   PubMed Web of Science ®Google Scholar
• RadtkeRAPharmacokinetics of levetiracetamEpilepsia200142Suppl 424711564121
   PubMed Web of Science ®Google Scholar
• RamaelSDaoustAOtoulCLevetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic studyEpilepsia2006b4711283516886975
   PubMed Web of Science ®Google Scholar
• RamaelSDe SmedtFToublancNSingle dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjectsClin Ther2006287344416861095
   PubMed Web of Science ®Google Scholar
• RamaelSDe SmedtFToublancNSingle-dose bioavalability of levetiravetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjectsClinical Therapeutics2006a287344416861095
   PubMed Web of Science ®Google Scholar
• RigoJ-MNguyenLBelachewSLevetiracetam: novel modulation of ionotropic inhibitory receptorsEpilepsia200041Suppl 735
   PubMed Web of Science ®Google Scholar
• ShorvonSDLowenthalAJanzDMulticenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizuresEpilepsia20004111798610999557
   PubMed Web of Science ®Google Scholar
• ShorvonSDvan RijckevorselKA new antiepileptic drug [editorial]J Neurol Neurosurg Psychiatry200272426811909894
   PubMed Web of Science ®Google Scholar
• ShorvonSDPyrrolidone derivativesLancet200120018859211741647
   PubMed Web of Science ®Google Scholar
• TsaiJJYenDJHsihMSEfficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled studyEpilepsia200647728116417534
   PubMed Web of Science ®Google Scholar
• ZonaCNiespodzianyIMarchettiCLevetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currentsSeizure2001102798611466024
   PubMed Web of Science ®Google Scholar